198 related articles for article (PubMed ID: 19687170)
1. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia.
Hoffer ZS; Roth RL; Mathews M
Psychosomatics; 2009; 50(4):317-24. PubMed ID: 19687170
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
[TBL] [Abstract][Full Text] [Related]
3. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
4. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
[TBL] [Abstract][Full Text] [Related]
5. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis.
Broekhof R; Gosselink MJ; Pijl H; Giltay EJ
Gen Hosp Psychiatry; 2012; 34(2):209.e1-3. PubMed ID: 21872335
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
7. Management of a patient with schizophrenia and underlying pituitary macroadenoma.
Ng KW; Lee J; Swapna V
Ann Acad Med Singap; 2010 Nov; 39(11):868-9. PubMed ID: 21165528
[No Abstract] [Full Text] [Related]
8. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Chen CK; Huang YS; Ree SC; Hsiao CC
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
[TBL] [Abstract][Full Text] [Related]
9. Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone.
Letmaier M; Painold A; Holl AK; Grohmann R; Vergin H
Int J Psychiatry Clin Pract; 2012 Jun; 16(2):153-6. PubMed ID: 22211772
[TBL] [Abstract][Full Text] [Related]
10. Reversal of symptomatic hyperprolactinemia by aripiprazole.
Wahl R; Ostroff R
Am J Psychiatry; 2005 Aug; 162(8):1542-3. PubMed ID: 16055781
[No Abstract] [Full Text] [Related]
11. Treatment with aripiprazole for hyperprolactinemia induced by pituitary microadenoma in a bipolar I disorder patient.
Chen ST; Hsiao YL
J Clin Psychopharmacol; 2010 Feb; 30(1):78-80. PubMed ID: 20075655
[No Abstract] [Full Text] [Related]
12. Hyperprolactinemia with aripiprazole: understanding the paradox.
Saraf G; Behere RV; Venkatasubramanian G; Rao NP; Varambally S; Gangadhar BN
Am J Ther; 2014; 21(3):e80-1. PubMed ID: 22357167
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.
Li X; Tang Y; Wang C
PLoS One; 2013; 8(8):e70179. PubMed ID: 23936389
[TBL] [Abstract][Full Text] [Related]
14. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.
Yasui-Furukori N; Furukori H; Sugawara N; Fujii A; Kaneko S
J Clin Psychopharmacol; 2010 Oct; 30(5):596-9. PubMed ID: 20814333
[TBL] [Abstract][Full Text] [Related]
15. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.
Lee BH; Kim YK; Park SH
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):714-7. PubMed ID: 16571367
[TBL] [Abstract][Full Text] [Related]
16. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection.
Ziadi Trives M; Bonete Llácer JM; García Escudero MA; Martínez Pastor CJ
J Clin Psychopharmacol; 2013 Aug; 33(4):538-41. PubMed ID: 23775053
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole treatment of risperidone-induced hyperprolactinemia.
Chen JX; Su YA; Wang SL; Bian QT; Liu YH; Wang N; Yang FD; Haile C; Kosten TR; Zhang XY
J Clin Psychiatry; 2009 Jul; 70(7):1058-9. PubMed ID: 19653986
[No Abstract] [Full Text] [Related]
18. Comment on "dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia".
Ishitobi M; Kosaka H; Shukunami K; Murata T; Wada Y
J Clin Psychopharmacol; 2011 Jun; 31(3):400-1; author reply 401. PubMed ID: 21532377
[No Abstract] [Full Text] [Related]
19. Resolution of haloperidol-induced hyperprolactinemia with aripiprazole.
Lorenz RA; Weinstein B
J Clin Psychopharmacol; 2007 Oct; 27(5):524-5. PubMed ID: 17873694
[No Abstract] [Full Text] [Related]
20. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
